Search Results
Aug 26, 2026, 02:36 ET Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
collaboration agreement under which SK Biopharmaceuticals will obtain an exclusive worldwide license to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy, with RISE3 trial topline results
More news about: Biohaven Ltd.
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
disease-driving antibodies with BHV-1300 in Graves' disease and BHV-1400 IgA Nephropathy, supporting advancement toward multiple registrational programs.Initiated pivotal Phase 3 study for BHV-1300 in Graves' disease with plans to initiate pivotal Phase 3 study for BHV-1400 in IgAN in 2H 2026.Ongoing
More news about: Biohaven Ltd.
Jul 21, 2026, 10:31 ET Acute Pain Market Forecast Signals Accelerated Growth at a CAGR of 12% During the Forecast Period (2026-2036), Driven by Novel Non-Opioid Therapies and Expanding Treatment Options | DelveInsight
Naltrexone and acetaminophen (DEPADE), LTG-001, Vocacapsaicin (CA-008), ATX101, HT-6184, Esflurbiprofen transdermal (TK-254Rx), CT001, Alenura (VNX001), BHV-2100, and others.Discover what is the future of the acute pain treatment market @
More news about: DelveInsight Business Research, LLP
Jul 20, 2026, 07:30 ET Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload
entered into a clinical supply agreement with Regeneron Pharmaceuticals, Inc. to evaluate BHV-1530 in combination with cemiplimab (Libtayo), building on preclinical data demonstrating synergistic activity between BHV-1530's TopoIx payload and immune checkpoint blockade.NEW
More news about: Biohaven Ltd.
Jun 30, 2026, 07:30 ET Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator
the patients who are participating in this study and to the sites whose dedication makes this possible."About OpakalimOpakalim (BHV-7000) represents a next-generation, selective Kv7.2/7.3 potassium channel activator targeting a clinically validated mechanism of action for the treatment
More news about: Biohaven Ltd.
Jun 29, 2026, 07:30 ET Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
profound.About BHV-1300BHV-1300, the first MoDE, is a small-molecule extracellular IgG1,2,4 degrader that leverages the body's natural hepatic clearance pathways to selectively eliminate disease-driving IgG subclasses. Critically differentiated from FcRn inhibitors: BHV-1300 spares IgG3
More news about: Biohaven Ltd.
Jun 01, 2026, 07:30 ET Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
disabling conditions. BHV-8100 has the potential to change that. BHV-8100 provides astrocytic lactate to neurons, correcting metabolic dysfunction, improving bioenergetics and offering real hope to the millions of patients to reverse the relentless decline in cognition and eyesight."BHV-8100 is an oral,
More news about: Biohaven Ltd.
May 27, 2026, 07:30 ET Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
diseases today reported compelling results regarding its proprietary extracellular MoDE™ (BHV-1300) and TRAP™ (BHV-1400) degrader platform. The new patient data from its BHV-1300 MoDE degrader for Graves' disease and BHV-1400 TRAP degrader for IgA nephropathy is being presented today at Biohaven's R&D
More news about: Biohaven Ltd.
May 26, 2026, 07:30 ET Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
randomized, double-blind, placebo-controlled studies in refractory focal epilepsy to support registration.About Opakalim Opakalim (BHV-7000) is Biohaven's next-generation, selective Kv7.2/7.3 potassium channel activator that targets a clinically validated mechanism of action for the treatment
More news about: Biohaven Ltd.
May 04, 2026, 16:02 ET Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
expected in 2H 2026.Lead TRAP and MoDE Extracellular Protein Degraders (BHV-1400 and BHV-1300)BHV-1400: Pivotal study initiation in IgAN study expected mid-year 2026BHV-1300: Pivotal study initiation in Graves' disease expected mid-year 2026.Capital
More news about: Biohaven Ltd.
Mar 19, 2026, 07:30 ET Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
realized until four weeks beyond the final dose was administered, suggesting the drug may support extended dosing intervals. In the Phase 3 study BHV2000-301, examining patients with a neuromuscular disorder, taldefgrobep-treated participants achieved statistically significant reductions in total body
More news about: Biohaven Ltd.
Mar 07, 2026, 17:51 ET TTW Picks Best 50 Heritage Travel Destinations in the World for 2026
Karachi Jinnah International Airport (KHI)Baltit Fort, Hunza – Gilgit Airport (GIL)Derawar Fort – Bahawalpur Airport (BHV) / Multan Airport (MUX)Chaukhandi Tombs, Karachi Region – Karachi Jinnah International Airport (KHI)Buddhist Ruins of Takht-i-Bahi –
More news about: Travel And Tour World
Mar 02, 2026, 16:05 ET Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
applications include BHV-1420 in membranous nephropathy, BHV-1450 in pemphigus vulgaris, myasthenia gravis, and encephalitis, BHV-1440 in Graves' disease and thyroid eye disease, BHV-6500 in type 1 diabetes, BHV-1490 in cryoglobulinemia, Waldenstrom's macroglobulinemia and IgM neuropathy, BHV-1310 for management
More news about: Biohaven Ltd.
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
BHV-1955 targeting the oxytocin receptor centrally for the treatment of tinnitus;BHV-2120, oral small molecule TRPM3 inhibitor for epilepsyBHV-8555, a brain penetrant, oral small molecule preventing a-synuclein aggregation in Parkinson's disease; andBHV-8100, a brain-penetrant,
More news about: Biohaven Ltd.
Dec 24, 2025, 13:00 ET Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
expansion cohorts BHV-1400 for IgAN and BHV-1300 for Graves' disease;expectations for the company's recently initiated Phase 2b study with taldefgrobep alfa in obesityoncology clinical stage assets;and emerging data from its ongoing clinical trial with BHV-7000 in adult focal
More news about: Biohaven Ltd.
Dec 11, 2025, 07:00 ET Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
a total of 31 participants were treated with the combination of BHV-1510 and cemiplimab, with BHV-1510 doses ranging from 2-2.75 mg/kg Q3W and 1.25-1.5 mg/kg D1D8Q3W. Cemiplimab was given at 350 mg Q3W.Across all doses BHV-1510, was generally well tolerated with a safety profile differentiated
More news about: Biohaven Ltd.
Nov 10, 2025, 06:58 ET Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
continued progress across our key programs and clinical-stage assets including: MoDE™ and TRAP™ degrader programs, where our two lead assets, BHV-1300 and BHV-1400, show compelling evidence to change the treatment paradigm in immune-mediated diseases; opakalim, a novel Kv7 ion channel activator, for the
More news about: Biohaven Ltd.
Nov 04, 2025, 20:06 ET FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
Key areas of focus over the near term include: 1) Clinical-stage, lead extracellular degraders for IgA nephropathy (BHV-1400) and Graves' disease (BHV-1300); 2) Opakalim, Kv7 ion channel activator, pivotal trials in adult focal epilepsy and depression; and 3) Taldefgrobep alfa, myostatin-activin
More news about: Biohaven Ltd.
Sep 24, 2025, 17:31 ET Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at a CAGR of 14% During the Study Period (2020-2034) | DelveInsight
Vocacapsaicin (CA-008), ATX101, HT-6184, TK-254Rx (esflurbiprofen transdermal), CT001, Alenura (VNX001), BHV-2100, and others.By 2034, among all the therapies, the highest revenue is expected to be generated by NURTEC ODT/VYDURA (rimegepant),
More news about: DelveInsight Business Research, LLP
Sep 12, 2025, 08:45 ET Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: Levi & Korsinsky, LLP
Sep 11, 2025, 19:40 ET BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (2) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (3) all the foregoing, once revealed, was likely to
More news about: THE ROSEN LAW FIRM, P. A.
Sep 11, 2025, 08:45 ET Shareholders that lost money on Biohaven Ltd.(BHVN) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely
More news about: The Gross Law Firm